This inventor holds 4 USPTO granted patents. Top assignee: Yunbaiyao Zhengwu Science and Technology (Shanghai) Co., Ltd.. Active years: 2021-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021-2025
Title: Zhengwu Shen: Innovator in Cancer Treatment
Introduction
Zhengwu Shen is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds for cancer treatment. With a total of 4 patents to his name, his work is recognized for its potential impact on medical therapies.
Latest Patents
Zhengwu Shen's latest patents include innovative compounds that show promise in the fight against cancer. One of his notable inventions is the "Imidazotriazine thiobenzamide derivative, and preparation method and application thereof." This patent provides a new derivative formula, along with a preparation method and its application in drug development for cancer treatment. Another significant patent is the "Thioamide derivative and preparation method and application thereof," which describes a new thioamide compound with high antitumor activity. This compound can be utilized for antitumor therapy, either alone or in combination with other drugs.
Career Highlights
Zhengwu Shen is associated with Yunbaiyao Zhengwu Science and Technology (Shanghai) Co., Ltd., where he continues to advance his research and development efforts. His work focuses on creating effective pharmaceutical solutions that address critical health challenges.
Collaborations
Zhengwu collaborates with notable colleagues, including Bin Deng and Hongzhu Bian, to enhance the scope and impact of his research. Their combined expertise contributes to the innovative environment at their company.
Conclusion
Zhengwu Shen stands out as a key figure in the development of cancer treatment innovations. His patents reflect a commitment to advancing medical science and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile